Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.

The FDA issued a complete response letter (CRL) to a new drug application (NDA) for 177 Lu-edotreotide (ITM-11) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors ...

HR-positive disease accounts for approximately 70% to 80% of breast cancer diagnoses and carries a risk of recurrence that ...

Sagar Lonial, MD, discusses why to take an individualized approach despite the trial's findings supporting discontinuation of lenalidomide at 2 years. Sagar Lonial, MD, of the Winship Cancer Institute ...

IMMUNO-BIOMAP targets the clinical uncertainty around who benefits from first-line immunotherapy, who experiences early failure, and whether fixed two-year treatment durations are necessary in ...

Deep remissions were frequent, with uMRD4 achieved in 86% (blood) and 84% (marrow), rising to 96% in both compartments among CR/CRi responders. Liso-cel CAR T plus ibrutinib delivers deep remissions ...

ASCO 2026 data show ePRO remote symptom monitoring cuts ER visits and costs, enabling faster toxicity detection and safer ...

OncoPRO unites oncology practices to streamline ePRO remote symptom monitoring, improving enrollment, workflow integration, ...

Accelerated approval relied on significantly higher MRD-negative CR at 10^-5 by next-generation flow in patients achieving CR or better: 41% with IberDd vs 21% with DVd (P<.0001). EXCALIBER-RRMM ...

REZILIENT3 randomized 285 previously untreated adults globally to zipalertinib plus platinum chemotherapy versus chemotherapy alone, using PFS as the primary endpoint in advanced/metastatic ...

Breakthrough Device designation enables prioritized FDA interaction and potentially expedited review for a diagnostic addressing a life-threatening disease with substantial unmet screening need.

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...